Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Poliovax, IPOL, IPV
Synonyms :
poliovirus vaccine inactivated
Class :
Vaccines, Viral Vaccines, Inactivated; Vaccines, Travel
Brand Name :
Poliovax, IPOL, IPV
Synonyms :
poliovirus vaccine inactivated
Class :
Vaccines, Viral Vaccines, Inactivated; Vaccines, Travel
Dosage Forms & Strengths
Injectable suspension (IM/SC)
5 mL/vial
Both adults and children can be protected against this illness with the use of the polio vaccination
Adults (18 years of age or older) living in the US are not advised to receive routine vaccinations; nevertheless, adults who are unvaccinated or only partially immunized and are exposed to wild poliovirus should receive a 3-dose course of vaccinations
SC/IM of 0.5 mL two doses spaced one to two months apart, or 3rd dose six to twelve months later, OR
three doses spaced more than a month apart or sufficient to finish the three doses altogether
Adults who have had all recommended vaccinations may need to take one booster dose if they plan to visit regions where there is a high risk of exposure to polio
Dose Adjustments
Limited data is available
Dosage Forms & Strengths
Injectable suspension (IM/SC)
5 mL/vial
Refer to the adult dosing
immunosuppressants may diminish the therapeutic effect of Vaccines
immunosuppressants may diminish the therapeutic effect of Vaccines
immunosuppressants may diminish the therapeutic effect of Vaccines
immunosuppressants may diminish the therapeutic effect of Vaccines
immunosuppressants may diminish the therapeutic effect of Vaccines
May decrease the diagnostic effect when combined with tuberculin Tests
May decrease the diagnostic effect when combined with tuberculin Tests
corticosteroids may diminish the therapeutic effect of vaccines
corticosteroids may diminish the therapeutic effect of vaccines
corticosteroids may diminish the therapeutic effect of vaccines
corticosteroids may diminish the therapeutic effect of vaccines
corticosteroids may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
it may reduce the therapeutic efficacy of vaccines
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may decrease the therapeutic effect of Immunosuppressants
acetaminophen/doxylamine/dextromethorphan
may decrease the therapeutic effect of acetaminophen
tixagevimab and cilgavimab (Investigational)
may decrease the therapeutic effect of COVID-19 Vaccines
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
lansoprazole, amoxicillin, and clarithromycin
may decrease the therapeutic effect when combined with vaccine
may decrease the therapeutic effect when combined with vaccine
may decrease the therapeutic effect when combined with vaccine
may decrease the therapeutic effect when combined with vaccine
may decrease the therapeutic effect when combined with vaccine
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
because of its immunosuppressive properties, ofatumumab SC reduces the effects of the poliovirus vaccine
teplizumab lessens the inactivated poliovirus vaccine's effects
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
may decrease the effects of each other
may increase the toxic effect of Immunosuppressants
siponimod reduces the immunosuppressive effects of the poliovirus vaccine inactivated
the immunosuppressive effects of secukinumab reduce the effects of the poliovirus vaccine inactivated
may diminish the therapeutic effect of other vaccines
vaccinia immune globulin intravenous (Rx)
may diminish the therapeutic effect of other vaccines
may diminish the therapeutic effect of other vaccines
may diminish the therapeutic effect of other vaccines
may diminish the therapeutic effect of other vaccines
melphalan decreases the activity of poliovirus vaccine inactivated by antagonism.
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may enhance the adverse/toxic effect of vaccines
may increase the toxic effect of tildrakizumab
the poliovirus vaccine's inactivation caused by pharmacodynamic antagonist is lessened by anakinra
because belimumab has immunosuppressive properties, it lessens the effects of the poliovirus vaccine inactivated
cortisone counteracts the pharmacodynamic antagonist-inactivated poliovirus vaccine's effects
cyclosporine reduces the poliovirus vaccine's inactivating effects through pharmacodynamic antagonistic interactions
everolimus reduces the effects of the poliovirus vaccine when pharmacodynamic antagonists are present
Actions and Spectrum:
Actions:
The purpose of the inactivated poliovirus vaccine (IPV) is to protect against poliovirus infection and to stop the paralytic illness known as poliomyelitis. Previously, the live attenuated oral poliovirus vaccine was used, and it occasionally caused vaccine-associated paralytic poliomyelitis (VAPP). Later, an intramuscular or subcutaneous injection of an inactivated poliovirus vaccination was created to remove the danger of VAPP. At the moment, only the injectable form of the poliovirus vaccination is utilized in the United States.
Spectrum:
There are three different serotypes of the poliovirus: Type 1, Type 2, and Type 3. Every serotype represents a unique strain of the virus. The purpose of the inactivated poliovirus vaccination is to protect against all three serotypes. For any of the three serotypes of poliomyelitis to not cause cases, his broad immunity is essential. The poliovirus is present in the IPV in inactivated, or dead, forms. By inactivating the virus, recipients of the vaccination are guaranteed to be protected against contracting polio. Still, it helps the immune system identify and retain the virus, shielding the body from further exposure.
Frequency defined
>10%
Injection site swelling (11%)
Irritability (7-65%)
Injection site pain (13%)
Fever >39 degrees Celsius (38%)
Tiredness (4-61%)
Injection site tenderness (29%)
1-10%
Crying (1%)
Erythema at injection site (3%)
Vomiting (1-3%)
Induration at injection site (1%)
Black Box Warning:
Inactivated poliovirus vaccine should not be given to those who have previously experienced hypersensitivity to any of its ingredients, including polymyxin B, formaldehyde, neomycin, 2-phenoxyethanol, or streptomycin.
Before giving the shot, find out about the patient’s history of vaccine hypersensitivity, particularly any reactions to an earlier dose of IPV or a comparable vaccination. If a patient experiences a severe allergic response, the immunization facility should have epinephrine and other suitable therapeutic measures on hand to handle the situation.
If someone experiences a serious allergic reaction (anaphylaxis or anaphylactic shock) within 24 hours of receiving the first dosage of the inactivated poliovirus vaccine, do not give them more doses.
Contraindication/Caution:
Contraindications
Cautions
Pregnancy consideration:
No data is available regarding the administration of the drug during pregnancy.
Breastfeeding warnings:
No data is available regarding the excretion of drug in breast milk.
Pregnancy category: C
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology:
Three strains of the inactivated virus that, after vaccination, causes an antibody reaction
These products stimulate the development of endogenously generated antibodies, which transmits active immunity.
Protection from disease has a long duration (years), although its onset is rather delayed.
Duration: Undetermined
Pharmacodynamics:
N/A
Pharmacokinetics:
N/A
Administration:
Don’t administer intravenously.
Don’t give medication into or close to blood vessels.
For newborns and young children, the optimum location is the mid-lateral aspect of the thigh.
For adults and older children, the deltoid is the recommended location.
Give no more than four weeks apart between doses.
may be given alone or concurrently with other vaccinations.
Keep separate from other vaccinations.
Patient information leaflet
Generic Name: poliovirus vaccine inactivated
Pronounced: poh-lee-oh-vahy-ruhs vak-seen in-ak-tuh-vey-tid
Why do we use poliovirus vaccine inactivated?
The main and most important goal of the inactivated poliovirus vaccine is to prevent polio, a highly contagious viral disease brought on by the poliovirus. In severe cases, polio can be lethal and cause paralysis.
Inactivated (killed) poliovirus strains are included in the vaccination. This indicates that although the virus has lost its ability to spread, it still has the capacity to elicit an immunological response. In people who have had vaccinations, the inactivated form of the virus cannot cause polio.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
